Intellia Therapeutics (NTLA) catalysts

Upcoming FDA decisions and readouts we track for Intellia Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 11 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Intellia Therapeutics (NTLA, listed on Nasdaq). It concerns Lonvoguran ziclumeran (lonvo-z) (Hereditary angioedema (HAE)).

First on the list: the PDUFA date for Lonvoguran ziclumeran (lonvo-z) (Hereditary angioedema (HAE)), dated 10 Mar 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker: NTLA
Next catalyst: 10 Mar 2027
Type: PDUFA date
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Intellia Therapeutics NTLA · Nasdaq	Lonvoguran ziclumeran (lonvo-z)	Hereditary angioedema (HAE)	10 Mar 2027 in 154d	PDUFA date	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing headline: "FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027." Would be among the first in vivo CRISPR therapies to reach an FDA decision. Source: 8-K exhibit 99.1, filed 08 Sep 2026 · verified 11 Sep 2026

Companies working on related conditions

Pharvaris N.V. (PHVS)Hereditary angioedema, on-demand treatment

Also due in Q1 2027

ImmunityBio (IBRX)PDUFA date for ANKTIVA (nogapendekin alfa) plus BCG, 06 Jan 2027
Cullinan Therapeutics (CGEM)PDUFA date for Zipalertinib, 27 Feb 2027
Apnimed (APMD)PDUFA date for AD109 (Oxnimbi), 28 Feb 2027
Arcutis Biotherapeutics (ARQT)PDUFA date for ZORYVE (roflumilast) cream 0.05%, 23 Feb 2027
Belite Bio (BLTE)PDUFA date for Tinlarebant, 12 Feb 2027
Dyne Therapeutics (DYN)PDUFA date for z-rostudirsen (DYNE-251), 21 Jan 2027